Rexahn initiates Phase Ib clinical trial of RX-3117 for treatment of solid tumors
RX-3117 has broad spectrum anti-tumor activity against 80 different human cancer cell lines (including NSCLC, breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 12 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.01/10/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Bladder Cancer | Brain | Brain Cancers | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Clinical Trials | Colon Cancer | Colorectal Cancer | Kidney Cancer | Neurology | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Renal Cell Carcinoma | Urology & Nephrology